Acrivon Therapeutics, Inc. (ACRV) Form 8-K — Jun 17, 2026
Stockholders approved the Amended and Restated 2022 Equity Incentive Plan at the 2026 Annual Meeting, increasing the share reserve by 3 million shares to an aggregate of 8,606,723 shares available for issuance. The plan also provides for an automatic annual increase of 5% of fully diluted shares through 2032 to support employee retention and incentive programs. Directors Michael Tomsicek and Charles Baum were elected as Class I directors to serve until the 2029 Annual Meeting.
Key figures
- Iso Limit
- 16820169
- Director Comp Limit
- 750000
- Share Increase Approved
- 3000000
- Aggregate Shares Reserved
- 8606723
Price after filing
Close on the filing date to close N calendar days later (from $1.52). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.